EDSA vs. DTIL, IKNA, KPTI, RENB, ARTV, OTLK, VNRX, PEPG, ATNM, and STTK
Should you be buying Edesa Biotech stock or one of its competitors? The main competitors of Edesa Biotech include Precision BioSciences (DTIL), Ikena Oncology (IKNA), Karyopharm Therapeutics (KPTI), Renovaro (RENB), Artiva Biotherapeutics (ARTV), Outlook Therapeutics (OTLK), VolitionRx (VNRX), PepGen (PEPG), Actinium Pharmaceuticals (ATNM), and Shattuck Labs (STTK). These companies are all part of the "pharmaceutical products" industry.
Edesa Biotech vs.
Precision BioSciences (NASDAQ:DTIL) and Edesa Biotech (NASDAQ:EDSA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, media sentiment, dividends, analyst recommendations, profitability, earnings and community ranking.
Edesa Biotech has lower revenue, but higher earnings than Precision BioSciences. Precision BioSciences is trading at a lower price-to-earnings ratio than Edesa Biotech, indicating that it is currently the more affordable of the two stocks.
Precision BioSciences presently has a consensus target price of $47.00, indicating a potential upside of 910.75%. Edesa Biotech has a consensus target price of $21.00, indicating a potential upside of 950.00%. Given Edesa Biotech's higher probable upside, analysts plainly believe Edesa Biotech is more favorable than Precision BioSciences.
In the previous week, Precision BioSciences had 1 more articles in the media than Edesa Biotech. MarketBeat recorded 4 mentions for Precision BioSciences and 3 mentions for Edesa Biotech. Edesa Biotech's average media sentiment score of 0.20 beat Precision BioSciences' score of -0.31 indicating that Edesa Biotech is being referred to more favorably in the news media.
Precision BioSciences has a beta of 1.55, suggesting that its stock price is 55% more volatile than the S&P 500. Comparatively, Edesa Biotech has a beta of 0.55, suggesting that its stock price is 45% less volatile than the S&P 500.
38.0% of Precision BioSciences shares are held by institutional investors. Comparatively, 5.5% of Edesa Biotech shares are held by institutional investors. 4.5% of Precision BioSciences shares are held by company insiders. Comparatively, 22.6% of Edesa Biotech shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Precision BioSciences received 68 more outperform votes than Edesa Biotech when rated by MarketBeat users. However, 77.78% of users gave Edesa Biotech an outperform vote while only 69.06% of users gave Precision BioSciences an outperform vote.
Precision BioSciences has a net margin of 11.48% compared to Edesa Biotech's net margin of 0.00%. Precision BioSciences' return on equity of -23.69% beat Edesa Biotech's return on equity.
Summary
Precision BioSciences beats Edesa Biotech on 10 of the 16 factors compared between the two stocks.
Get Edesa Biotech News Delivered to You Automatically
Sign up to receive the latest news and ratings for EDSA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Edesa Biotech Competitors List
Related Companies and Tools
This page (NASDAQ:EDSA) was last updated on 5/22/2025 by MarketBeat.com Staff
Buy EDSA Stock Free EDSA Stock Alerts